BioPharm International
February 01, 2013
Features
26
2
Development requirements and regulatory guidance for biosimilars and biobetters.
February 01, 2013
Boot Camp Business Guide
26
2
NIBRT's Michael Lacey provides an overview of biopharmaceutical facility design and operation.
February 01, 2013
Guest Editorial
26
2
Ever since Twitter launched in 2006 and Facebook became mainstream, most industries have sought ways to connect with their consumers through social media.
February 01, 2013
Regulatory Beat
26
2
Shortages spur efforts to overhaul manufacturing oversight.
February 01, 2013
Features
26
2
Innovative products and a range of indications drive the therapeutic antibody market.
February 01, 2013
Features
26
2
A look at vaccine history, markets, manufacturing, and overcoming the scale-up dilemma.
February 01, 2013
Features
26
2
Project: transfer a manual concentration/diafiltration process for siRNA production.
February 01, 2013
Perspectives on Outsourcing
26
2
Is the contract-only CMO an endangered species?
February 01, 2013
Features
26
2
Tony Hitchcock of Cobra Biologics discusses challenges posed by production of viral vectors for vaccines.
February 01, 2013
Features
26
2
Eastern Europe is moving towards a goal of harmonized regulations.
February 01, 2013
Global Reports
26
2
India's biopharmaceutical industry is valued at $2 billion a year with 20 companies producing biosimilars and 50 products available in the domestic market.
February 01, 2013
Manufacturing Best Practices
26
2
Improvement strategy should be linked to business strategy.